EP08.02-081 Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC

Cabozantinib, a multitargeted receptor tyrosine kinase inhibitor (TKI), promotes an immune-permissive environment that may enhance immune checkpoint inhibitor (ICI) activity. COSMIC-021 (NCT03170960) is a multicenter phase 1b study evaluating cabozantinib plus atezolizumab in advanced solid tumors. In COSMIC-021, cabozantinib plus atezolizumab demonstrated encouraging clinical activity in a cohort of patients with advanced NSCLC (aNSCLC) previously treated with ICIs (Neal. ASCO 2020. Abstr 9610). Outcomes of cabozantinib plus atezolizumab in first or second-line aNSCLC (cohort 8 [C8]) and previously-treated EGFR mutant aNSCLC (cohort 9 [C9]) are presented.